Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 280 No 7502 p585
17 May 2008

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Representative ordered to pay damages following prescription fraud

A medical representative who supplied stolen prescriptions in a widespread fraud, which cost the NHS hundreds of thousands of pounds, is facing financial ruin after a High Court ruling last week.

Girish Pandya, of Kenton Lane, Harrow, was ordered to pay £213,448 in damages to the London Strategic Health Authority (LSHA), as well at least £190,000 in legal costs and £156,000 in interest after the civil court hearing in London.

In a lengthy written judgement, Sir Andrew Park said Mr Pandya was “involved in the organisation and implementation of the fraud or frauds” that involved seven London pharmacies. Between 1998 and 2001, the pharmacies used thousands of forged prescription forms to obtain large payments from the NHS for prescriptions that had not been dispensed.

Sir Andrew said that there were at least 3,773 forged forms — taken from 40 doctors’ surgeries in London — and the total cost to the NHS was calculated at £429,249.

In the only fraud detailed by the judge, Sir Andrew said Mr Pandya would receive regular supplies of prescription drugs in return for his role in the scam.

“There is no evidence of what Mr Pandya did with the drugs which were supplied to him by the pharmacy without paying for them,” said the judge. “It has been conjectured that he may have sold them on the black market.”

Sir Andrew said there was “considerable force” in the suggestion that Mr Pandya stole the forms himself, as he often had “unsupervised access to rooms where some prescription forms were located”. He refused permission for Mr Pandya, who has never been prosecuted in the criminal courts, to appeal against his ruling.

The court heard that individuals or companies that owned or ran seven pharmacies involved in the fraud have already settled with the LSHA after agreeing to pay substantial sums, interest and costs.

Back to Top


©The Pharmaceutical Journal